News

NanoMedSyn will participate to the International Symposium on Inorganic  and Environmental Materials ISIEM2023 in Montpellier, France. The symposium will focus...

The 3rd Immune-Oncology World Congress Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted...

Invest in Biomed, 7th edition. For innovative companies with high potential in healthtech, Eurobiomed continues its support.

Day of the cluster : Biotherapy Innovation Occitanie October 13, 2022 in Montpellier https://www.agence-adocc.com/biotherapie-innovation-occitanie/  

NanoMedSyn is co-organiser of  the 2nd Symposium on delivery and target for pediatric tumors, on 23-24th June in Switzerland (Schwarzsee)....

10th Antibody Industrial Symposium 2022 We are proud to announce our participation to the 10th Antibody Industrial Symposium 2022 (AIS2022)...

Henry-Vincent Charbonné (1953-2021)

NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.

NanoMedSyn has signed a research agreement with the French National Research Agency within the framework of the "Plan France Relance...

NanoMedSyn has been distinguished for its Growth Path by Bpifrance and joins the "Excellence" community.

NanoMedSyn has signed a 3-year Innovation Contract with the Occitanie Region for a "Research and Development of New Targeted Drugs"...

Dr. Marcel Garcia, co-founder and Scientific Director, is appointed President and Scientific Director of NanoMedSyn by the General Assembly. This...

This article demonstrates the involvement of acid phosphatases in the higher efficacy of AMFA-labelled enzyme therapy. J Cell Mol Med....

Shire and NanomedSyn enter into research agreement for potential lysosomal storage disorder treatment. This collaboration was stopped in September 2019....

NanoMedSyn  develops an efficient  treatment for refractory Pompe disease published by Journal of Controlled Release. J Control Release 2017, 269:15-23.

First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002/anie.201607824R2  

Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe's disease....

Lire l'article complet

Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours...

http://www.rare2015.com/index.php